Full Press Release Details
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience.
Registration: Click here to register
During the webcast, Dr. Maccecchini will share progress on the ongoing pivotal Phase 3 trial in early AD, the FDA's feedback on the continued development of the PD program, and other key initiatives. The event will feature a brief presentation followed by a live Q&A session, offering attendees the opportunity to engage directly with the Company’s CEO.
The webcast is open to shareholders, patients, investigators, and all interested parties eager to learn more about Annovis’ current work and future direction. Attendees are encouraged to submit questions in advance by emailing ir@annovisbio.com.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements relate to the Company’s clinical trials, including patient enrollment, the efficacy and safety of Buntanetap, and expected outcomes. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
101 Lindenwood Drive
Alexander Morin, Ph.D.
Director, Strategic Communications